Inhibitory characteristics of citrullinated telopeptides of type I and II collagens for autoantibody binding in patients with rheumatoid arthritis

Rheumatology

Volumn 45, Issue 11, 2006, Pages 1364-1369

  Koivula, M K ^a   Aman S ^a   Alasaarela, E ^a   Karjalainen, A ^a   Hakala, M ^b   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

Anti CCP antibodies; Autoantibodies; Citrullination; Rheumatoid arthritis; Telopeptide; Type I collagen; Type II collagen

Indexed keywords

ALANINE; ARGININE; AUTOANTIBODY; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BINDING, COMPETITIVE; COLLAGEN TYPE I; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC;

EID: 33750209167     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel113     Document Type: Article

References (23)

1. Nijenhuis S, Zendman AJW, Vossenaar ER, Pruijn GJM, van Venrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chem Acta 2004;350:17-34.
2. Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005;10:54-64.
3. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 2003;25:1106-18.
4. Yamada R. Peptidylarginine deiminase type 4, anticitrullinated peptide antibodies, and rheumatoid arthritis. Autoimmun Rev 2005;4:201-6.
5. Worthington J, John S. Association of PAD14 and rheumatoid arthritis: A successful multidisciplinary approach. Trends Mol Med 2003;9:405-7.
6. Yamada R, Suzuki A, Chang X, Yamamoto K. Peptidylarginine deiminase type 4: Identification of a rheumatoid arthritis-susceptible gene. Trends Mol Med 2003;9:503-8.
7. Vossenaar ER, Radstake TR, van der Heijden A et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004;63:373-81.
8. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology, 2005;44:1374-82.
9. Nienhuis RLF, Mandema E. A new serum factor in patients with rheumatoid arthritis the antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.
10. Young BJJ, Mallya RK, Leslie RDG, Clark CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med 1979;2:97-9.
11. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
12. Girbal-Neuhauser E, Durieux JJ, Arnaud M et al. The epitopes targeted by the rheumatoid arthritis-associated antifflaggrin auto-antibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
13. Schellekens GA, Visser H, de Jong BAW et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
14. Rantapää-Dahlqvist S, de Jong BAW, Berglin E et al. Antibodies against cyclic citrultinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-49.
15. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004;50:709-15.
16. Koivula M-K, Åman S, Karjalainen A, Hakala M, Risteli J. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Ann Rheum Dis 2005;64:1443-50.
17. Koivula M-K, Ramberg J, Åman S, Karjalainen A, Hakala M, Risteli J. Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxyterminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis. Clin Chem Lab Med, 2005;43:1400-5.
18. Burkhardt H, Sehnert B, Bockermann R, Engström Å, Kalden JR, Hohndahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005;35:1643-52.
19. Suzuki A, Yamada R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K. Anti-citrullinated collagen type I antibody is a target of autoinummity in rheumatoid arthritis. Biochem Biophys Res Commun 2005;333:418-26.
20. Lundberg K, Nijenhuis S, Vossenaar ER et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7:R458-67.
21. Clague RB, Shaw MJ, Holt PJ. Incidence and correlation between serum IgG and IgM antibodies to native type II collagen in patients with chronic inflammatory arthritis. Ann Rheum Dis 1981;40:6-10.
22. Rowley M, Tait B, Mackay IR, Cunningham T, Phillips B. Collagen antibodies in rheumatoid arthritis. Significance of antibodies to denatured collagen and their association with HLA-DR4. Arthritis Rheum 1986;29:174-84.
23. Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis. Arthritis Rheum 2004;50:380-386.